On December 16, 2025 Iambic, a clinical-stage life sciences and technology company advancing novel medicines through its AI-driven discovery and development platform, reported that Tom Miller, Ph.D. (Co-Founder and Chief Executive Officer) and Fred Manby, Ph.D. (Co-Founder and Chief Technology Officer) will present at the 44th Annual J.P. Morgan Healthcare Conference. Iambic’s presentation will take place on Tuesday, January 13, 2026, at 4:30 p.m. PT at the Westin St. Francis Hotel in San Francisco.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Iambic will highlight strategic progress over the past year, which has laid the groundwork for significant upcoming milestones. Highlights include:
Presentation of Phase 1/1b data for IAM1363, Iambic’s lead AI-designed drug candidate, demonstrating anti-tumor activity across HER2-wild-type and HER2-mutated cancers and a favorable safety profile
Research collaboration and drug supply agreement with Jazz Pharmaceuticals to evaluate IAM1363 in combination with zanidatamab in HER2-positive breast cancer
Presentation of IAM1363 pre-clinical NSCLC data at the World Conference on Lung Cancer showing potent anti-tumor activity and significant tumor regression across HER2-amplified and HER2-mutant NSCLC models, including greater anti-tumor activity compared to zongertinib
Technology-enablement collaboration with Revolution Medicines, leveraging Iambic’s NeuralPLexer protein-ligand prediction model to accelerate oncology target discovery
Continued development and validation of Enchant, Iambic’s multimodal model for predicting clinical and preclinical endpoints, with industry-leading performance benchmarks
Raising an oversubscribed financing exceeding $100 million to support clinical expansion and continued platform growth
The company will also preview key activities anticipated in the near-term, including:
Upcoming clinical data readouts, further defining IAM1363’s best-in-class potential and combination opportunities across HER2-driven cancers
Initiation of additional clinical trials for its potential first- and best-in-class programs, underscoring continued progress in advancing multiple pipeline candidates
Additional discovery and technology collaborations with biopharmaceutical partners, reflecting strong industry demand for Iambic’s platform capabilities
Advancement of new internal programs, broadening the company’s AI-driven discovery pipeline
Release of next-generation NeuralPLexer and Enchant models, featuring increased prediction breadth, expanded property coverage, and broader modality applicability
Iambic will also be at the conference to meet with investors and potential biopharmaceutical and technology partners.
(Press release, Iambic Therapeutics, DEC 16, 2025, View Source [SID1234661472])